Daraxonrasib pancreatic cancer pill: FDA approval covers previously treated metastatic disease

November 21, 2026
2 mins read
Two researchers in lab coats working at benches in a cancer research laboratory
Researchers at work in a cancer research laboratory. The RASolute 302 results behind the daraxonrasib approval were published in the New England Journal of Medicine. (Photo: Wikimedia Commons, public domain)

Patients with advanced pancreatic cancer and their families may be asking whether daraxonrasib offers another treatment option after chemotherapy. The medicine, developed by Revolution Medicines and marketed as RASONQUE, is an oral drug designed to target active RAS proteins. The FDA approved it on August 26, 2026, for adults with previously treated metastatic pancreatic ductal adenocarcinoma.

Pancreatic ductal adenocarcinoma is the most common form of pancreatic cancer, and RAS mutations occur in more than 90% of these tumors. Daraxonrasib is a RAS(ON) multiselective tri-complex inhibitor. It binds cyclophilin A to block active, GTP-bound RAS signaling. In the Phase 3 RASolute 302 trial, which included 500 patients, median overall survival was 13.2 months with daraxonrasib and 6.7 months with chemotherapy. Median progression-free survival was 7.2 months and 3.6 months, respectively.

For patients, the practical question is whether the approved treatment fits their situation. The FDA approval covers adults with previously treated metastatic pancreatic ductal adenocarcinoma. Patients should discuss treatment decisions and eligibility with their oncology team; tumor testing and individual clinical findings may inform care.

The drug’s mechanism is intended to address multiple active RAS mutations, including mutations such as G12D and G12V. In the trial’s RAS G12 population, which accounted for 91.8% of participants, median overall survival was 13.2 months with daraxonrasib and 6.6 months with chemotherapy. Median progression-free survival was 7.3 months and 3.5 months, respectively.

Is daraxonrasib effective for all pancreatic cancer patients?

No. Trial results do not show that it works for every patient. The drug is approved for a defined group of adults with previously treated metastatic pancreatic ductal adenocarcinoma. Response and risks depend on individual clinical findings. It should not be described as a cure or a replacement for every standard treatment.

The FDA also granted breakthrough therapy designation in September 2026 to daraxonrasib combined with gemcitabine and nab-paclitaxel as a first-line treatment for metastatic pancreatic cancer. The Phase 3 RASolute 303 trial of that combination is ongoing.

Tejal Somvanshi

Meet Tejal Somvanshi, a soulful wanderer and a staunch wellness advocate, who elegantly navigates through the enchanting domains of Fashion and Beauty with a natural panache. Her journey, vividly painted with hues from a vibrant past in the media production world, empowers her to carve out stories that slice through the cacophony, where brands morph into characters and marketing gimmicks evolve into intriguing plot twists. To Tejal, travel is not merely an activity; it unfolds as a chapter brimming with adventures and serendipitous tales, while health is not just a regimen but a steadfast companion in her everyday epic. In the realms of fashion and beauty, she discovers her muse, weaving a narrative where each style narrates a story, and every beauty trend sparks a dialogue. Tejal seamlessly melds the spontaneous spirit of the media industry with the eloquent prose of a storyteller, crafting tales as vibrant and dynamic as the industry she thrives in.

Leave a Reply

Your email address will not be published.

Renault Twingo E-Tech electric city car, side and rear three-quarter view
Previous Story

Renault Twingo E-Tech price starts at £14,745 in the UK after grant

Latest from Health

Don't Miss